As covid-19 is a disease related to respiration and breathing, it affects all parts of respiratory system such as neuromuscular breathing, conducting airways, the respiratory airways and alveoli, the pulmonary vascular endothelium, and pulmonary blood flow.
Although bronchial blockers support in single lung ventilation and reduce hemodynamic stress, there may be a risk of slow lung deflation, secretion removal, bronchial mucosal damage, etc. There are methods to escalate the lung deflation process e.g. apnoea and using a modified device called intravenous T-connector extension set.
Recent developments in bronchial blocker devices market include:
In February 2021, Teleflex announced the acquisition of Z-medica, a medical device manufacturer in Wallingford, Conn focusing on sale, development and marketing of hemorrhage control products. The acquisition is expected to generate revenue growth and contribute up to $70 million of revenue in fiscal year 2021.
Cook Medical in 2020 launched its Hercules 100 Transnasal Esophageal balloon in US. The balloon is designed for esophageal procedures and is a toll used by physicians to treat strictures. With the launch, patients can be treated on the same day that they are checked. The Hercules 100 balloon is 140 cm shorter than the previous one and can be inserted transnasally where anaesthesia is not required.
Masimo, a world leader in innovative monitoring technologies announced its acquisition of TNI medical AG, a ventilation company in Germany in 2020. Increasing demand for TNI’s sfotflow technology during covid-19 led Masimo to take this decision. TNI’s novel softflow technology provides highflow, warmed and humidified respiratory gases to breathing patients suffering from serious pulmonary conditions. The softflow technology provides respiratory support by generating high flow of room air and oxygen.
With the exceeding significance of bronchial blocker devices in the field of medical science, the bronchial blocker devices manufacturers have introduced revolutionary solutions for improved medical aid to the patients. The need for efficient medical devices has fuelled the growth with the growing requirements in anaesthesia. With the developing technology and advancements in the healthcare industry, medical device manufacturers are constantly innovating their products to cater to the application specific needs of medical care.
Key players are enabling high-end technology and expertise to provide greater precision to the medical professionals with advancements in the bronchial blocker devices. Apart from stand-alone bronchial blocker devices, researchers are seen innovating with products, by introducing a consolidated setup of bronchial blocker devices with single lumen tubes along with high-resolution cameras for visual monitoring. With effective navigation to the bronchi and sterile catheters, the bronchial blocker devices are a complete solution for the anesthetic needs in the healthcare industry. The bronchial blocker devices market is, therefore, expected to experience next-generation advancements in the coming years by device manufacturers.
Bronchial blockers are devices which are inserted into the tracheal tube after a tracheal intubation. The device is mainly used to block one of the main bronchus of the lungs (left or right). It helps achieve a controlled one sided ventilation of the lungs during a thoracic surgery. The lung tissue below the obstruction will collapse, thereby allowing the surgeon’s view and access to relevant structures within the thoracic cavity. Lung separation is achieved using these bronchial blocker devices.
Brochial blockers are used to avoid contamination and control distribution of ventilation during thoracic surgeries. There are two techniques to achieve the one lung ventilation; they are the use of double lumen endotracheal tube and the other is the use of bronchial blockers to allow the collapse of the bronchi distal to the occlusion. In paediatric patients for whom the smallest double-lumen endotracheal tubes may be too large, generally undergo the single lung ventilation method.
In 1936, Magill used a long tube with an inflatable cuff at its end to achieve the one lung bronchial blockage. Since then, there have been a number of bronchial blocker devices introduced into the market. These included the Fogarty vascular embolectomy catheter, single-lumen endotracheal tube and the wire-guided endobronchial blocker.
The Fogarty catheters, although not designed as a bronchial blocker are especially advantageous in cases where the bronchus is small like in paediatric cases and also is widely used in patients who are critically ill. The single-lumen endotracheal tube are the most expensive but are the best choice for difficult airways, selective lobar blockage and robotic surgeries. The wire-guided endobronchial blocker like the Arndt blocker requires a large single lumen tube and takes a long time for the lung to collapse
The global bronchial blocker device is apprehended to see impressive growth in the forecast period due to increasing demand by large number of patient population. Although the double-lumen endotrachealtubes is a more popular method for the lung separation, the bronchial blockers are gaining popularity due to some of its advantages such as use in paediatric patients and in airways that are difficult to enter and reach target site.
Segment by Product Type
- Fogarty vascular embolectomy catheter
- Single-lumen endotracheal tube
- Wire-guided endobronchial blocker
Segment by End Users
- Ambulatory Surgical Centers
The global market is segmented by product type, end users and geography. Based on the product type, it is segmented into Univent System, Arndt Endobronchial Blockers, Cohen Flexitip Endobronchial Blockers, Folly Catheters and EZ-Blocker. Fogarty catheter is expected to dominate the bronchial blocker devices sector due to ease of use in pediatric patients and is popular due to its comparative low cost.
On the basis of regional presence, global market is segmented into five key regions viz. North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America is the dominating region owing to the presence of leading players, favourable reimbursement policies and increased number of thoracic surgeries. Manufacturers are targeting developed regions due to rise in thoracic surgeries in the developing countries.
Europe is the second leading region due increased healthcare spending per person, and government support. Asia Pacific is also expected to grow at a higher rate owing to large patient pool, and product awareness due to medical conferences. These factors are likely to drive the growth during the forecast period globally.
Some of the key players are Fuji Systems Corporation, Teleflex Inc., Cook Medical, Edwards Life sciences, ETView Medical Ltd., Daiken Medical Co Ltd, and others
Fact.MR offers custom research services that help clients to get specific research solutions
We are committed towards customer satisfaction and quality service.